Who are Aralast NP's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Prolastin-C.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aralast-np.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Aralast NP — Competitive Intelligence Brief

Aralast NP (Aralast NP) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Protease inhibitor (augmentation therapy). Area: Pulmonology / Respiratory.

marketed Protease inhibitor (augmentation therapy) Alpha-1 protease inhibitor (AAT); neutrophil elastase inhibition Pulmonology / Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Aralast NP (Aralast NP) — National Institute of Allergy and Infectious Diseases (NIAID). Aralast NP is a purified human alpha-1 protease inhibitor (AAT) that replaces deficient or dysfunctional alpha-1 antitrypsin to protect lung tissue from enzymatic degradation.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Aralast NP TARGET	Aralast NP	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	Protease inhibitor (augmentation therapy)	Alpha-1 protease inhibitor (AAT); neutrophil elastase inhibition
Prolastin-C	Prolastin-C	Grifols Therapeutics LLC	marketed	Alpha-1 protease inhibitor (augmentation therapy)	Alpha-1 antitrypsin (AAT); serine protease inhibitor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Protease inhibitor (augmentation therapy) class)

National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aralast NP — Competitive Intelligence Brief. https://druglandscape.com/ci/aralast-np. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab